Login
$CLNN
$3.65 -$0.01 (0.27%) After hours

Company Executives

Officer Age In this role Source
Robert Etherington Also a director
President and Chief Executive Officer
59 Since 2013
13 years
Morgan R. Brown
Chief Financial Officer
57 Since 2022
4 years
Mark Mortenson
Chief Science Officer
67 Since 2013
13 years

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Directors
9
serving now
Independent
8 of 8
stated in the proxy; 1 not stated
Average tenure
7.7 years
from year joined
CEO also chairs the board
No
David J. Matlin
Director Age On board Independent Committees Other public boards 2025 pay Source
David J. Matlin
64 2020
6 years
Independent
Nominating and Corporate Governance Committee · Chair
TriSalus Life Sciences Inc. $80,873
Robert Etherington
59 2013
13 years
Not stated None stated None stated Paid as CEO
Shalom Jacobovitz
65 2013
13 years
Independent
Compensation Committee · Chair
None stated $62,379
Alison H. Mosca
53 2019
7 years
Independent
Audit Committee · Chair
None stated $63,881
Jonathon T. Gay
49 2020
6 years
Independent None stated None stated $54,387
Vallerie V. McLaughlin, M.D.
62 2021
5 years
Independent None stated None stated Not stated
Reed N. Wilcox
78 2013
13 years
Independent None stated None stated Not stated
Arjun JJ Desai, M.D.
44 2023
3 years
Independent
Compensation Committee
TriSalus Life Sciences Not stated
Matthew Kiernan AM, Ph.D., DSc
59 2023
3 years
Independent None stated None stated Not stated

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

7 disclosed in the proxy filed Apr 10, 2026
4Life Research LLC
an entity controlled by David Lisonbee, a stockholder, debt holder, and board member of a subsidiary of Clene
Amount not stated
2024

Exclusive supply agreement and license agreement for dietary supplement products, amended April 25, 2024; we receive royalties and product revenue from 4Life.

Kensington Clene 2024, LLC
an entity controlled by Alison Mosca, an independent director
$8.0 million
December 2024

Purchase of senior secured convertible promissory notes (2024 SSCP Notes).

4Life Research LLC
an entity controlled by David Lisonbee, a 5% or greater stockholder and board member of a subsidiary of Clene
$1.0 million each
December 2024

Purchase of 2024 SSCP Notes.

La Scala Investments, LLC
an entity controlled by David Lisonbee, a 5% or greater stockholder and board member of a subsidiary of Clene
$1.0 million each
December 2024

Purchase of 2024 SSCP Notes.

David Matlin
an independent director and chairman of our Board
Approximately $0.5 million
October 2024

Participation in October 2024 private placement of common stock, pre-funded warrants and common warrants.

Kensington Clene 2021, LLC
an entity controlled by Alison Mosca, an independent director
Approximately $0.8 million
October 2024

Participation in October 2024 private placement of common stock, pre-funded warrants and common warrants.

SymBiosis II, LLC
a 5% or greater stockholder
Approximately $2.0 million
October 2024

Participation in October 2024 private placement of common stock, pre-funded warrants and common warrants.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support